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Abstract: Colorectal cancer (CRC) is one of the most common and mortal types of cancer. There is
increasing evidence that some polyunsaturated fatty acids (PUFAs) exercise specific inhibitory actions
on cancer cells through different mechanisms, as a previous study on CRC cells demonstrated for
two very long-chain PUFA. These were docosahexaenoic acid (DHA, 22:6n3) and arachidonic acid
(ARA, 20:4n6) in the free fatty acid (FFA) form. In this work, similar design and technology have been
used to investigate the actions of both DHA and ARA as monoacylglycerol (MAG) molecules, and
results have been compared with those obtained using the corresponding FFA. Cell assays revealed that
ARA- and DHA-MAG exercised dose- and time-dependent antiproliferative actions, with DHA-MAG
acting on cancer cells more efficiently than ARA-MAG. Sequential window acquisition of all theoretical
mass spectra (SWATH)—mass spectrometry massive quantitative proteomics, validated by parallel
reaction monitoring and followed by pathway analysis, revealed that DHA-MAG had a massive
effect in the proteasome complex, while the ARA-MAG main effect was related to DNA replication.
Prostaglandin synthesis also resulted as inhibited by DHA-MAG. Results clearly demonstrated the
ability of both ARA- and DHA-MAG to induce cell death in colon cancer cells, which suggests a direct
relationship between chemical structure and antitumoral actions.
Keywords: colorectal cancer; proteomics; SWATH; docosahexaenoic acid; arachidonic acid; HT-29
cells; monoacylglycerols
1. Introduction
The fat content of a normal diet consists mainly of triacylglycerols (TAG) (about 90% of total
ingested lipids) and small amounts of sterols and phospholipid esters, as well as fat-soluble vitamins
(A, D, E, and K) [1]. The fatty acid (FA) distribution on the glycerol backbone of TAG influences their
absorption, distribution, and tissue uptake [2]. Free FA (FFA) and sn-2-monoacylglycerol (sn-2 MAG),
the two hydrolysis products of dietary TAG, are absorbed from the lumen into polarized enterocytes in
the small intestine. Polyunsaturated FAs (PUFAs) are better absorbed when they are esterified at the
sn-2 position of the glycerol molecule, while the type of FA at the remaining locations also influences
their intestinal absorption [2–5].
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Arachidonic acid (ARA, 20:4n6) is a long-chain PUFA (LCPUFA) belonging to the n-6 family.
This molecule is the precursor of the biosynthetic pathway leading to the production of prostaglandin
PGE2, thromboxanes and other metabolites involved in the regulation of various physiological
processes, e.g., inflammation and immune function [6]. Docosahexaenoic acid (DHA, 22:6n3) is one
of the predominant LCPUFAs in the structural phospholipids of the human brain and retina, and it
accumulates within the fetal neural tissue during pregnancy and the postnatal period [7]. At present,
fish oil constitutes the main source of DHA, although alternatively it can be industrially obtained from
several microorganisms, mainly from marine origin, e.g., the unicellular microalga Crypthecodinium
cohnii, which contains large amounts of DHA [8].
The n-6/n-3 ratio is commonly used as an index to evaluate the nutritional quality of dietary FA,
and it has particular relevance on human health. n-3 LCPUFAs help to reduce inflammation, while
most n-6 LCPUFAs tend to increase it. An imbalanced n-6/n-3 ratio contributes to the development of
diseases, while an adequate balance helps to maintain and even improve health [9,10].
Different mechanisms have been proposed for the anticancer actions of the various LCPUFAs,
including suppression of neoplastic transformation, inhibition of cell proliferation and enhancement
of apoptosis [11]. This last phenomenon is morphologically characterized by a decrease in cell and
nuclear volume, chromatin condensation and DNA fragmentation, and the presence of lipid bodies,
without changes in organelle integrity [12]. Morin et al. [13,14] demonstrated a reduction in cell growth
and the induction of apoptosis caused by DHA-MAG, eicosapentaenoic acid (EPA, 20:5n3)-MAG,
and docosapentaenoic acid (DPA, 22:5n3)-MAG, in colon and lung cancer cell lines. In addition, MAG
derived from monounsaturated FAs (MUFAs) such as oleic acid (OA, 18:1n9), and saturated FAs (SFAs)
such as palmitic acid (PA, 16:0), have been related to the decrease in the activity of MRP2 (protein 2
associated with multidrug resistance) in Caco-2 cells at low concentrations [15]. Also, Philippoussis
et al. [3] showed that murine T-cells undergo a rapid apoptosis following treatment with different
MAG types.
One of the aspects to be considered in the performance of MAG as a cancer inhibitor is the
mechanisms for entering into cells. Whereas Schultess et al. [16] stated that MAGs are absorbed by
passive diffusion, Ho and Storch [5] suggested that they require a protein-mediated process. Little is
known about these input mechanisms, although different enzymes related to biosynthesis and lipid
degradation are supposed to be involved in this process. For instance, Acyl-CoA synthetases (ACS) play
a critical role in the transport of FA into cells by making this transport unidirectional [17]. Mashek and
Coleman [18] found that the overexpression of ACS4, which is located on the mitochondrial-associated
membrane in hepatocytes, increases EPA incorporation into cell lipids by 67% during a 3-h labeling
period in COS-1 cells. MAG-lipase and α/-β-hydrolase domain 6 (ABHD6) and ABHD12 are enzymes
which are also involved in intracellular degradation of MAG in many tissues. Poursharifi et al. [19]
showed that the suppression of ABHD6 caused the accumulation of 1-MAG-containing saturated FA
in pancreatic islets and INS-1 cells and also in white and brown adipose tissues, while the changes
in 2-MAG content was modest. Gadja and Storch [20] suggest an important role on this subject
for a liver-FA binding protein (LFABP), which is part of a complex along with microsomal TAG
transport protein (MTP), CD36, and ApolipoproteinB48 (ApoB48), and is responsible for budding
of prechylomicron transport vesicles (PCTV) from the endoplasmic reticulum (ER). Circulating FA
and MAG enter the enterocyte via the basolateral membrane where they can be bound to LFABP,
and bloodstream-derived FA and MAG are primarily oxidized or incorporated into phospholipids.
Taken together, all this information supports the fact that for MAG there is a mediated transport across
the cell membrane of enterocytes.
Currently, there is a growing research effort focused on the production of functional nutrients
such as structured lipids. However, few studies have focused on assessing the effects of ARA- and
DHA-MAG in colon cancer cells and the related molecular mechanisms. In a previous study focused
on FFA, we demonstrated that DHA-FFA inhibited HT-29 cells proliferation to a higher extent than
ARA-FFA did, with either proteasome or DNA replication, respectively, being the main mechanisms
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affected [21]. Here, we used the same cellular model, study design, and technology to investigate the
actions of DHA and ARA-MAG in colorectal cancer (CRC) cells, and the results are compared with
those reported for the corresponding FFA. For this objective, cell viability and cell cytotoxicity assays
have been performed, and the biological pathways that are affected by these two MAGs have also been
studied by means of sequential window acquisition of all theoretical mass spectra (SWATH)—mass
spectrometry (MS) global protein quantitation followed by pathway analysis.
2. Materials and Methods
2.1. Oil Samples and Purification of MAG
DHASCO® (40% DHA, a mixture of the oil extracted from the unicellular alga Crypthecodinium
cohnii and high oleic sunflower oil) and ARASCO® (40% ARA, a mixture of an oil extracted from the
unicellular fungi Mortierella alpina and high oleic sunflower oil) oils were supplied by Martek Bioscience
Corporation (Columbia, MD, USA). Purification of ARA- and DHA-MAG was carried out according to
the methodology described by González-Fernández et al. [22] based on a chromatography process.
Briefly, both DHASCO® and ARASCO® oils were subjected to an enzymatic hydrolysis with porcine
lipase. Then, MAGs were separated from the remaining hydrolysis products (mainly FFA and glycerol)
using an open chromatography column with silica gel as stationary phase and a hexane/acetone
mixture as mobile phase. Once MAG mixtures were obtained, another open chromatography column
with silver nitrate as stationary phase was used to purify either DHA-MAG or ARA-MAG. Liquid
chromatographic fractions were collected in test tubes and analyzed by gas chromatography (GC)
to determine the purity grade according to Rodríguez-Ruiz et al. [23]. To this end, about 1 mg of
each fraction was weighed into test tubes next to 1 mL of n-hexane and 1 mL of freshly prepared
transesterification reagent (methanol and acetyl chloride 20:1 v/v). Then, the tubes were placed
in a thermoblock at 100 ◦C for 30 min. After that, the mixtures were cooled at room temperature
and 1 mL of distilled water was added. Samples were shaken and centrifuged (2500 rpm, 3 min)
and the upper n-hexane layer collected and stored in numbered vials at −20 ◦C until GC analysis.
The equipment used for FA methyl esters (FAME) analysis was a GC device (Focus, Thermo Electron,
Cambridge, UK) equipped with flame ionization detector (FID) and an Omegawax 250 capillary column
(30 m × 0.25 mm ID × 0.25 µm film thickness) (Supelco, Bellefonte, PA, USA). The oven temperature
program was 90 ◦C (1 min), 10 ◦C/min to 100 ◦C (3 min), 6 ◦C /min to 260 ◦C (5 min). The injector
temperature was 250 ◦C with split ratio 50:1, and injector volume was 4 µL. The detector temperature
was 260 ◦C. The flow of carrier gas (N2) was 1 mL/min. Peaks were identified by retention times
obtained for known FAME standards (PUFA No. 1, 47033; methyl linoleate 98.5% purity, L6503;
and methyl stearidonate 97% purity, 43959 FLUKA) from Sigma, (St. Louis, USA), and FA contents
were estimated by using methyl pentadecanoate (15:0; 99.5% purity; 76560 Fluka) from Sigma as
internal standard.
2.2. Cell Assays
All assays were accomplished using the HT-29 colon cancer cell line, which was supplied by the
Technical Instrumentation Service of University of Granada (Granada, Spain). Cell cultures and cell
assays, that is, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test, lactate
dehydrogenase (LDH) assay and caspase-3 activity, were performed as previously described [21].
The number of cells used in the cell assays ranged from 5 × 103 for LDH assay to 1 × 107 for caspase-3
assay, as previously described [21,24].
2.3. SWATH-MS Differential Abundance Proteomics Analysis
HT-29 cells, cultured in media supplemented with 600 µM of either DHA- (n = 6) or ARA-MAG
(n = 6) at 24 h, and the same cells with no acyl species added (control group, n = 6) were recovered and
lysed. Protein extracts were obtained, and protein was precipitated with TCA/acetone for removing
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contaminants. Then, 40 µg protein for each sample were subjected to trypsin digestion, and massive
protein relative quantitation was assessed following a SWATH approach as described in Ortea et al. [21].
Briefly, this approach consisted on three steps: (i) an MS/MS peptide library was built from the peptides
and proteins identified in data-dependent acquisition (DDA) shotgun nanoLC-MS/MS runs from
the samples, using Protein Pilot software (v5.0.1, Sciex) with a human Swiss-Prot protein database
(20,200 protein entries, appended with the RePliCal iRT peptides (PolyQuant GmbH, Bad Abbach,
Germany) and downloaded from UniProt on March 2017). Main settings used in Protein Pilot were
iodoacetamide as Cys alkylation, trypsin as enzyme, TripleTOF 5600 as instrument, and thorough ID
as search effort. The false discovery rate (FDR) was set to 0.01 for both peptides and proteins; (ii) each
sample was analyzed with a variable SWATH LC-MS method; and (iii) protein quantitative data for
the proteins contained in the peptide library were obtained from the SWATH runs by extracting the
corresponding fragment ion chromatograms using the MS/MSALL with SWATH Acquisition MicroApp
(v.2.0, Sciex). Peptide retention times were calibrated in all the SWATH runs using the RePliCal iRT
peptides, spiked into each sample according to manufacturer’s instructions. To be confident on the
proteins being identified and quantified, only those showing confidence scores above 99% and FDR
below 1% were included in the analysis. For both kinds of LC-MS analysis, DDA and SWATH, a hybrid
Q-TOF mass spectrometer (Triple TOF 5600+, Sciex, Redwood City, CA, USA) coupled on-line to
nano-HPLC (Ekspert nLC415, Eksigent, Dublin, CA, USA) was used. For higher sensitivity, both DDA
and SWATH runs were performed at nano-flow (300 nL/min) in a 25 cm long × 75 µm internal diameter
column (Acclaim PepMap 100, Thermo Scientific, Waltham, MA, USA) using a 120 min gradient from
5% to 30% B (A: 0.1% FA in water; B: 0.1% in ACN).
2.4. Pathway and Gene Ontology (GO) Analysis
Advaita Bio’s iPathwayGuide (Advaita Corporation, Plymouth, MI, USA) was used for analyzing
the significantly impacted pathways and for GO analysis. We considered a restrictive scenario, namely
a differential expression threshold of log (fold change) 1.0 (that is, fold change 2.0) and adjusted p-value
0.01, in order to have more confidence in selecting the proteins that presented real expression changes.
Data were analyzed in the context of pathways obtained from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database (Release 78.0+/06-02, Jun 16).
2.5. Validation by Parallel Reaction Monitoring (PRM) Analysis
Several protein changes corresponding to the main significant affected pathways were subjected
to validation using targeted quantitation by micro-HPLC PRM on a Triple TOF 5600+ (Sciex). Skyline
software (v4.2.0) [25] was used for designing and optimizing a PRM acquisition method for all of the
targeted proteins. Two to six proteotypic peptides for each protein were selected according to the
following criteria: (i) enzyme: trypsin [KR/P] with 0 missed cleavages; (ii) 7–16 amino acid residues;
(iii) carbomidomethylation of cysteines as structural modification; (iv) excluding peptides containing
methionine; and (v) excluding the N-terminal amino acids. Transitions were filtered according to
the following criteria: (i) +2 and +3 precursor charges; (ii) y and b product ion types; (iii) product
ions from (m/z > precursor)—1 to last ion; (iv) method match tolerance 0.055 m/z; (v) a maximum
of 10 product ions; and (vi) resolving power of 15,000 for MS/MS filtering. The HPLC gradient
consisted of 5–22% buffer B (A: 0.1% FA in water; B: 0.1% FA in ACN) at 5 µL/min for 45 min, plus
5 min at 95% B and another 6 min at 5% B for re-equilibration. The column used was a 15 cm long
× 300 µm internal diameter C18 column (Dionex Benelux B.V., Amsterdam, Netherland). Five to six
individual samples (4 µg per sample) from each of the groups, DHA-MAG, ARA-MAG, and control,
and two blank samples, were analyzed with the developed PRM, and the resulting chromatograms for
all the monitored peptides were imported into Skyline and manually curated. Three injection replicates
were used for calculation of the coefficients of variation (CV) for each of the monitored peptides.
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2.6. Statistical Analysis
For cell assay results, statistical significance was determined using generalized linear models
(GZLMs) using Statgraphics Plus 4.0 (Statistical Graphics Corp., Rockville, MD, USA). For SWATH-MS
protein quantitation, data were analyzed following Ortea et al. [21]. Briefly, quantitative data
were normalized for inter-run variability, and differences in protein abundance were assessed by
applying a Student’s t-test, checking for multiple testing underestimation of p-values by obtaining
a q-value estimation for FDR using the qvalue R package [26]. For impact pathway and GO analysis,
iPathwayGuide software calculated a p-value using a hypergeometric distribution. The p-values were
adjusted using FDR correction for pathways and Bonferroni correction for GO analysis. For PRM
validation of protein changes, statistical analysis was performed using the ‘group comparison’ function
in Skyline. Briefly, Skyline performed pairwise group comparisons for each protein using a Student’s
t-test on the log2 transformed summed transition peak area for all the peptides from that protein,
adjusting the p-values for multiple testing with the Benjamini-Hochberg correction.
3. Results
3.1. DHA- and ARA-MAG Showed Differential and Concentration-Dependent Effects on HT-29 Cell Viability,
Cell Membrane Integrity, and Apoptosis
The present study was conducted using the well-established HT-29 human colon cancer cell line.
The purities of the assayed MAGs were 98.0% and 98.7% for DHA and ARA, respectively. According
to González-Fernández et al. [22], during MAG purification process an acyl migration occurs quickly,
so the concentrations of 1(3)-MAG balance with 2-MAG at one point that depends on several causes,
e.g., solvent type, pH, and temperature. Although the purified forms are mainly 2-MAG and these are
those added to cell cultures, in the culture medium the acyl-migration continues [27]. For this reason,
we generically refer to MAG instead of 2-MAG.
First, we tested the actions of ARA- and DHA-MAG in HT-29 cells. Cell cultures were treated
with different concentrations (50–600 µM) of ARA- and DHA-MAG for 48 and 72 h and then the MTT
assay was performed to measure cell viability and cell proliferation (Figure 1a). After 48 and 72 h
of treatment, the MTT assay revealed concentration-dependent inhibitory effects on HT-29 cells for
both assayed acyl species. Cell growth inhibition was exercised much better by DHA-MAG, with IC50
values of 135 and 115 µM for 48 and 72 h, respectively, while for ARA-MAG these values were 236 and
169 µM.
The actions of ARA- and DHA-MAG on cell membrane integrity measured by the LDH assay after
48 and 72 h of treatment, are shown in Figure 1b. The test assesses the release of the LDH enzyme into
the culture medium after cell membrane damage caused by MAG. The tested concentrations ranged
from 50 to 600 µM. No effect of DHA-MAG on the amount of LDH release was noted, while a 40%
increase in LDH activity after 72 h treatment was detected at the highest ARA-MAG concentrations.
To clarify whether ARA- and DHA-MAG were able to reduce cancer cell viability by promoting
apoptotic cell death, a classical marker of apoptosis, caspase-3, was determined. In this study, caspase
activation was evaluated in cells treated with ARA- and DHA-MAG at 300 and 600 µM for 90 min
(Figure 1c). Caspase-3 activity is expressed as the percentage of activity compared to that of the
untreated samples. As shown, a significant increase (up to 361%) of caspase-3 activity in the HT-29
cells was observed after 90 min exposure to DHA-MAG, while ARA-MAG did not show remarkable
effects as compared to the respective untreated controls.
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Figure 1. Plots showing results of cell assays. (a) Dose-dependent viability of HT-29 cells after
exposure to docosahexaenoic acid (DHA)- and arachidonic acid (ARA)-monoacylglycerol (MAG).
(b) Dose-dependent lactate dehydrogenase (LDH) rel ase from HT-29 c lon cancer cells after exposure
to DHA- and ARA-MAG. (c) Dose-dependent caspase-3 activity from HT-29 colon cancer cells in
comparison with untreated cells (control). Data represen the mean of thr e complete independent
experiments ± SD (error bars). Data were analyzed using generalized linear models (GZLMs). There
are no significant differences (p < 0.05) among series sharing the same le ter.
3.2. SWATH Quantitation of 1882 proteins Showed That DHA- and ARA-MAG Differentially Affect the Whole
Proteome of HT-29 Cells
Samples were analyzed by DDA nanoLC-MS/MS, and runs were searched against a human protein
database using Protein Pilot so tware. As a result, after integrating all three d ta sets, 2140 proteins
and 15,406 peptides were ident fied (FDR < 1% at both protein and peptide lev ls); the list of identified
proteins is shown in Table S1. The identified MS/MS spectra were compiled into a spectral library
containing 2002 prot ins. Using this library, chromatographic traces were xtracted from the SWATH
runs for 7653 peptides, corresponding to 1882 protein . SWATH-bas d qua tification normalized data
for these 1882 proteins in all the samples is s own in Table S2.
Tables S3 and S4 show the results for the diff rential abundance tes s for DHA-MAG vs. control
and for ARA-MAG vs. control, respe tively. For subsequent analyse , w cons dered a r strictive
scenario, namely p-value < 0.01 and two-fold change (FC), in order to have more c nfidence in selecting
the proteins pres nting actual expression changes. When addressing the changes in HT-29 cell proteome
caused by DHA-MAG, a total of 896 proteins showed changes in expression (189 up-regulated and
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707 down-regulated) (Figure 2a). Applying the same p-value and FC thresholds, only 70 proteins
revealed a differential abundance as a consequence of the exposure to the ARA-MAG supplemented
medium, 21 proteins being up-regulated and 49 down-regulated (Figure 2b). When looking for the
largest effects, extreme FCs (above 5.0) were found in 119 and six proteins (p-value < 0.01) for DHA-
and ARA-MAG, respectively (Tables S3 and S4, respectively). Therefore, it is clear than DHA-MAG
produces a deeper effect than ARA-MAG on HT-29 cancer cells. When comparing the differentially
abundant proteins (p-value < 0.01 and FC ≥ 2.0) in both tested groups, only 45 proteins were commonly
being affected. Multivariate analyses of SWATH-based data including all 1882 quantitated proteins
showed a complete separation of all groups: DHA-MAG, ARA-MAG, and control (Figure 2c and
Figure S1).Nutrients 2019, 11, 2984 8 of 20 
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shown in Figure 3. After FDR correction, only one pathway was found to be significantly impacted 
by DHA-MAG, namely the proteasome pathway (KEGG: 03050), with 30 proteins down-regulated 
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replication (KEGG: 03030), with a DNA polymerase and three helicase subunits down-regulated 
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The biological processes GO component most affected by DHA-MAG was nucleobase-
containing compound biosynthetic process (adjusted p-value 2.66 × 10–4) (Figure 3b), with 239 
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expression as a result of the addition of (a) DHA-MAG; and (b) ARA-MAG. Red dotted lines show
p-value < 0.01 and two-fold change cut-offs; proteins above these thresholds are shown in red. (c) Heat
map including all 1882 quantified proteins; samples treated with DHA-MAG and ARA-MAG are
separated from each other and from the control group.
3.3. Pathway and GO Analysis Showed Different Mechanisms of Action of DHA- and ARA-MAG on
HT-29 cells
The affected pathways and GO components were analyzed using iPathwayGuide software.
Significantly impacted pathways and over-represented GO gro ps accordi g to this analysis are
shown in Figure 3. After FDR correction, only one pathway was found to b significantly impacted
by DHA-MAG, amely the proteasome p thway (KEGG: 03050), with 30 proteins down-regulated
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(Figure 4). On the other hand, two pathways resulted as significantly affected by ARA-MAG, DNA
replication (KEGG: 03030), with a DNA polymerase and three helicase subunits down-regulated
(Figure 5); and pyrimidine metabolism (KEGG: 00240).
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Figure 3. Pathway impact and gene ontology (GO) analysis for DHA-MAG and ARA-MAG. (a) 
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Figure 3. Pathway i ct and gene ontology (GO) analysis for DHA-MAG and ARA-MAG.
(a) Significa tl i cted pathways and their associate adjusted p-values. (b,c) GO analysis showing
significant (adjusted p-values < 0.05) (b) biological processes or (c) cellular components.
The biological processes GO component most affected by DHA-MAG was nucleobase-containing
compound biosynthetic process (adjusted p-value 2.66 × 10−4) (Figure 3b), with 239 proteins
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presenting differential abundance (Table S5). For ARA-MAG, the only significantly over-represented
biological processes according to our GO analysis were those related to the G1/S transition of the cell
cycle (Figure 3b), presenting eight proteins being regulated (Table S5). Regarding GO analysis of
cellular components, DHA-MAG regulated proteins were mainly related to cytosol (adjusted p-value
2.05 × 10−20), but also from extracellular and nuclear origin (Figure 3c and Table S6), while no cellular
component resulted as over-represented as a consequence of ARA-MAG regulation.
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3.4. SWATH Proteomics Analysis was validated by PRM 
We developed a micro-HPLC PRM method to validate several of the protein changes previously 
found with the SWATH quantitative analysis workflow. Specifically, nine proteins were included in 
the PRM assay (Table 1): the most relevant pathways, as found in the pathway analysis, were 
represented by proteins MCM2 and MCM7 (helicase proteins from DNA replication pathway) and 
PSMF1, PSME3, and PSA3 (proteasome pathway); AIFM1 (apoptosis-inducing factor 1), as an 
apoptotic marker which we had found up-regulated in the SWATH analysis only in DHA-MAG 
treated cells but not in ARA-MAG, was also included in the validation assay; three other proteins 
showing SWATH-measured differences according to the compound used (ABHD2, up-regulated in 
ARA-MAG and not-significant in DHA-MAG; SRXN1, up-regulated in ARA-MAG and down-
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by ot ins MCM2 and MCM7 (helicase proteins from DNA replication pathway) and PSMF1, PSME3,
and PSA3 (proteasome pathway); AIFM1 (apoptosis-inducing factor 1), as an apoptotic marker which
we had found up-regulated in the SWATH analysis only in DHA-MAG treated cells but not in
ARA-MAG, was also included in the validation assay; three other proteins showing SWATH-measured
differences according to the compound used (ABHD2, up-regulated in ARA-MAG and not-significant
in DHA-MAG; SRXN1, up-regulated in ARA-MAG and down-regulated in DHA-MAG; and TEBP,
down-regulated in DHA-MAG and not-significant in ARA-MAG) were also included for validation of
the SWATH results. After optimization of the method for these nine proteins, a total of 27 proteotypic
peptides were used for targeted PRM validation (Table S7). As an indication of the precision of the PRM
assay, measured CVs were below 20% for all the peptides except for peptide TFVDYAQK (CV of 22%);
median CV for the entire peptide set was 9.0% (Figure S2 and Table S7). The effect of both compounds,
DHA-MAG and ARA-MAG, on the nine targeted proteins, as measured by PRM, is shown in Figure 6.
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Table 1. Differential abundance for the proteins subjected to validation. Fold-changes and statistical
significance are shown for both SWATH and Parallel Reaction Monitoring (PRM) analyses.
Protein ID Protein Name
ARA-MAG to Control
SWATH PRM Validation
FC q-Value SignificantChange FC
adj.
p-Value
Significant
Change
MCM2
DNA replication
licensing factor
MCM2
0.46 8.3 × 10−0 ↓ 0.56 2.1 × 10−2 ↓
MCM7
DNA replication
licensing factor
MCM7
0.37 6.4 × 10−4 ↓ 0.57 2.9 × 10−2 ↓
PSMF1
Proteasome
inhibitor PI31
subunit
0.44 7.4 × 10−3 ↓ 1.00 1.0 × 10+0 no
PSME3
Proteasome
activator complex
subunit 3
0.47 1.3 × 10−4 ↓ 0.81 3.7 × 10−2 ↓
PSA3
Proteasome
subunit alpha
type-3
1.05 3.6 × 10−1 no 1.18 2.2 × 10−1 no
ABHD2
Abhydrolase
domain-containing
protein 2
6.14 2.4 × 10−6 ↑ 5.81 0 ↑
SRXN1 Sulfiredoxin-1 4.81 1.3 × 10−4 ↑ 5.12 0 ↑
TEBP Prostaglandin Esynthase 3 0.97 3.6 × 10−1 no 1.03 8.7 × 10−1 no
AIFM1
Apoptosis-inducing
factor 1,
mitochondrial
1.24 6.7 × 10−2 no 1.42 1.3 × 10−1 no
Protein ID Protein Name
DHA-MAG to Control
SWATH PRM Validation
FC q-Value SignificantChange FC
adj.
p-Value
Significant
Change
MCM2
DNA replication
licensing factor
MCM2
0.29 4.8 × 10−6 ↓ 0.24 0 ↓
MCM7
DNA replication
licensing factor
MCM7
0.21 2.6 × 10−6 ↓ 0.16 0 ↓
PSMF1
Proteasome
inhibitor PI31
subunit
0.13 1.8 × 10−5 ↓ 0.50 2.1 × 10−2 ↓
PSME3
Proteasome
activator complex
subunit 3
0.13 1.4 × 10−7 ↓ 0.24 0 ↓
PSA3
Proteasome
subunit alpha
type-3
0.40 6.7 × 10−7 ↓ 0.31 0 ↓
ABHD2
Abhydrolase
domain-containing
protein 2
1.35 1.0 × 10−1 no 0.97 8.4 × 10−1 no
SRXN1 Sulfiredoxin-1 0.40 9.7 × 10−5 ↓ 0.38 7.0 × 10−4 ↓
TEBP Prostaglandin Esynthase 3 0.14 2.0 × 10−7 ↓ 0.08 0 ↓
AIFM1
Apoptosis-inducing
factor 1,
mitochondrial
2.34 1.6 × 10−6 ↑ 1.82 1.1 × 10−3 ↑
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4. Discussion
IC50 values obtained by the - and DHA-MAG are lower than those obtained
for both LCPUFAs in the FFA form ap lied to the same cell line [21]. These iffere r l t to
the existence of a protein-mediated transport for PUFA across cell membranes. In this regard, a specific
protein-mediated process has been reported for intestinal Caco-2 cells, which allows the entry of
LCPUFA into such cells [5], and both acyl forms, i.e., FFA and MAG, establish competition for the same
membrane-associated protein transporters (FAT, FATP, CD36, FABP). The findings of this work outline
other ones from Ramos Bueno et al. [24], who demonstrated that unspecific oil-derived ARASCO®-
and DHASCO®-MAG induced noticeable in vitro antitumor activity on HT-29 cells. Previous studies
demonstrated that DHA significantly decreases cancer cells proliferation [28]; while Pompeia et al. [12]
found dose- and time-dependent ARA-induced cytotoxicity in leukocytes, i.e., ARA at 10–400 µM
induced apoptosis, while at concentrations above 400 µM the noted effect was necrosis. Several
studies have discussed the relationship between FAs and mitochondrial permeability transition. Such
relation is modulated by a variety of effectors of cell death, including reactive oxygen species (ROS),
which are important messengers in normal-cell signal transduction and cell cycle being produced by
mitochondria after stimulation of the TNFα receptor [29,30]. Moreover, Scorrano et al. [29] showed that
ARA is a powerful permeability-transition inducer in MH1C1 cells, causing a release of cytochrome
c followed by cell death.
The LDH test is a colorimetric method suitable for the m asurement of cel m mbrane integrity.
It is based the m asurement of LDH enzyme activity whose increa e in the cultur supernatant is
proportional to the nu ber of lysed cells [31]. Until now, several authors have studied cell membrane
permeability to determine non-cytotoxic concentrations of MAG on different cell lines, such as Caco-2
and HT-29 cells, and no significant toxicity measured by the LDH assay was observed [15,24,32,33].
In this study, toxicity was found only after 72-h treatment at the highest ARA-MAG concentrations. This
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might be linked to the differential spatial configuration of both ARA- and DHA-MAG. The activities
of both ARA and DHA were previously checked in the FFA form, with a higher activity being noted
for ARA than for DHA [21,34], thus, after the intracellular hydrolysis of both MAGs, the action of the
ARA-MAG would still prevail. The low activity could be due to the fact that both ARA- and DHA-MAG
cannot be integrated effectively into cell membranes, since MAGs are low-polarity compounds and
therefore they cannot establish effective chemical links with membrane proteins on these structures [35].
In this regard, Dommels et al. [36] stated that the cytotoxic effects mediated by some PUFAs, e.g., ARA
and EPA, are due to the peroxidation products generated during lipid peroxidation and cyclooxygenase
activity. However, MAGs are known to be surface-active compounds, so they might show minor
cytotoxic effects on cells by disrupting cell membranes [32].
Caspase-3 is considered to be the most important effector of apoptosis and a marker for both
intrinsic and extrinsic pathways [37]. An important aspect to consider is the chemical structure of the
different MAGs, which affects the potency to induce apoptosis; in this regard, Philippoussis et al. [3]
concluded that SFA-based MAG had no effect on such phenomenon, while PUFA-MAGs were highly
potent to induce apoptosis in T-cells. The apoptotic activity noted here for DHA agrees with previous
findings [3,38,39], and the potency of both LCPUFA-MAGs was higher than that previously reported
for both FFA-based LCPUFAs [21]. Our findings demonstrated that DHA-MAG induces apoptotic
cell death via activation of caspase-3. The non-activation of caspase by ARA-MAG may be due to
the chemical structure of MAG, since in the FFA form such activity was detected [21]. These results
completely agree with those from Ho and Storch [5], who suggested the existence of a protein-mediated
process for MAG transport through cell membranes. Accordingly, LCPUFA-based MAGs could
reach high concentrations inside cells and would be able to perform effective apoptosis actions,
as reported here.
SWATH, one of the recently developed data-independent acquisition (DIA) MS strategies [40],
shows outstanding precision and accuracy even when used for proteome-wide quantitation [41].
SWATH performance is comparable to that of selected reaction monitoring (SRM), the golden standard
for protein and small molecule quantitation [41]. SWATH consists of acquiring MS/MS data in stepped
m/z fragmentation windows, and then matching the resulting fragment ions to peptides and proteins
using a previously generated MS/MS spectral library, so fragment ion chromatograms can be in-silico
extracted and used for label-free protein quantitation. Here we have used a SWATH v2.0 method,
with variable Q1 isolation windows according to the ion density found in previous DDA runs, which
has been described to improve peptide identification and quantification [42]. The results found in
our SWATH analysis, with DHA-MAG producing a deeper effect than ARA-MAG on the HT-29
cancer cell proteome, suggest that the decrease of cell viability and increase of apoptosis observed
should be produced by means of different mechanisms depending on the MAG tested. For comparing
these results to those found in our previous work [21], it has to be noted that both experiments (cell
cultures and cell assays) were run in parallel, and the analytical LC-MS methods and bioinformatics
analysis performed have been exactly the same. All LC-MS runs were combined in one dataset,
normalized for inter-run variability, and analyzed all together (SWATH extraction, pathways, and GO
analysis). When comparing the results with those previously obtained for DHA- and ARA-FFA [21],
284 (45 up-regulated and 239 down-regulated) and 73 (27 up-regulated and 46 down-regulated)
proteins, respectively, were reported for the FFA forms. Therefore, these previous results also showed
a deeper effect for DHA than for ARA. Within the DHA-derived molecules, MAG affected the HT-29
cell proteome more globally than FFA did (896 vs. 284 differentially expressed proteins, respectively),
although there is a protein core of 237 proteins that are common to both DHA forms (Figure S3). Taking
all these figures together, these results indicates that (i) DHA and ARA (in both forms, FFA and MAG)
differentially affect the whole proteome of HT-29 cells, suggesting that the decrease of cell viability
and increase of apoptosis observed should be produced by means of different mechanisms depending
on the molecule tested; and (ii) MAG have a much deeper effect than FFA only for DHA forms, not
for ARA. As an additional interesting result, we found PTGES3 (prostaglandin E synthase 3, TEBP,
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accession Q15185) was strongly down-regulated in DHA-MAG (fold-change 0.14, that is, seven times
less abundant in DHA-MAG than in the control group) (Table S3). This protein, also down-regulated as
an effect of DHA-FFA (fold-change 0.5, that is, two-fold less abundant in DHA-FFA than in control) [21],
belongs to the prostaglandin biosynthesis pathway, and catalyzes the conversion of prostaglandin H2
to prostaglandin E, that is, the next step to the transformation of arachidonic acid to prostaglandin
H2, which is catalyzed by COX-2. COX-2 is involved in regulation of apoptosis and proliferation of
colorectal, liver, pancreatic, breast, and lung cancer cells [43], and although we do not have quantitative
data for COX-2 in our results, the strong down-regulation of PTGES3 we found could mean that one of
the antitumor activities of DHA could be effected by means of the prostaglandin cascade, since it plays
an important role in antigen presentation and immune activation in cancer [44].
The significantly affected pathways were analyzed using iPathwayGuide software, which
implements an ‘impact analysis’ approach, taking into consideration not only the over-representation of
differentially expressed (DE) genes in a given pathway (i.e., enrichment analysis), but also topological
information such as the direction and type of all signals in a pathway, and the position, role,
and type of each protein [45]. Only the proteasome pathway resulted as significantly impacted by
DHA-MAG in our analysis. The proteasome is a large protein complex which main action is degrading
ubiquitinated-labeled proteins [46], and plays an important role in the regulation of many cellular
processes such as cell cycle, cell differentiation, signal transduction, inflammatory response, and antigen
processing. In Figure 4, a diagram of the different particles and proteins constituting the proteasome
are shown, highlighting the proteins that we have found to be significantly regulated as an effect of
DHA-MAG on HT-29 cancer cells. In our results, we found 30 proteins from the proteasome pathways
to be significantly down-regulated, comprising all the main particles: 11 proteins from the 20S core
particle and 14 proteins from the 19S regulatory particle, in both lid and base subunits. In addition,
the PA28-αβ and PA28-γ are also down-regulated. PA28-γ has been found in the nucleus and plays
an important role in the regulation of apoptosis and cell cycle progression [47]. Interestingly, proteasome
was the main pathway that was found to be affected by DHA-FFA in our previous study using the
same workflow [21]. In that case, 18 proteins from the proteasome complex resulted as down-regulated.
Since the number of DE proteins reached 30 in the case of DHA-MAG, we can conclude that both
forms of DHA affect the proteasome, but the MAG form induces its massive switch-off. Interestingly,
proteasome inhibitors, such as natural polyphenol compounds, have been tested in clinical trials as
drug candidates for treating different cancers, due to their ability to induce apoptosis and reduce cell
proliferation [48,49]. According to the strong down-regulation of the proteasome particles we have
found in our study, we suggest DHA-derived MAG, in addition to DHA-FFA as previously reported,
as one of these candidates that deserve further studies as an anticancer effector.
Two pathways resulted as significantly affected by ARA-MAG: DNA replication and pyrimidine
metabolism. Regarding the DNA replication pathway, POLE3, one of the proteins conforming the
DNA polymerase E, and three proteins from the helicase (MCM2, MCM3, and MCM7) were found
to be significantly down-regulated (Figure 5). In addition, the remaining helicase proteins, MCM4,
MCM5, and MCM6, which are not significant according to our threshold (above two-fold change),
are also affected to a certain extent, since corresponding fold-changes (case to control) found are 0.51,
0.55, and 0.51, respectively. The DNA helicase protein complex is responsible for unwinding the
duplex DNA helix ahead of the DNA synthetic machinery at the replication fork [50]. Since DNA
replication is linked to cell cycle progression and to DNA repair processes, it would be expected that
the down-regulation of the helicase-constituting proteins and POLE3 would have an inhibitory effect
on these other related processes. Actually, our results show that cell cycle pathway (KEGG: 04110),
even though is not significant in our pathway analysis (adjusted p-value of 0.214), is perturbed by the
addition of the ARA-MAG extract, since several proteins belonging to this pathway are regulated by
it (Figure S4a). The other pathway that resulted as significantly impacted according to our pathway
analysis was the pyrimidine metabolism pathway (KEGG: 00240) (adjusted p-value 0.041), where
ARA-MAG produces the under-expression of several proteins (Figure S4b). When comparing to the
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results obtained in the previous study using ARA-FFA, these two pathways, DNA replication and
pyrimidine metabolism, together with cell cycle, also resulted as significantly impacted in the pathway
analysis [21].
Interestingly, DHA-MAG also affects proteins from the DNA replication pathway (Figure S5),
showing four helicase proteins being down-regulated, although our pathway analysis does not report
this pathway as statistically significant due to the high global number of affected proteins. DNA
replication turned out to be significantly impacted in our previous study using DHA-FFA, and therefore
we can say that both forms of DHA induce a down-regulation of helicase proteins in addition to the
deep effect on the proteasome. In contrast, ARA-MAG, as was the case also for ARA-FFA [21], does
not induce a strong effect on the proteasome pathway (p-value of 0.661) since only two of the proteins
included in this pathway were found to be regulated, PSMF1 and PSME3, with fold-changes (case to
control) of 0.44 and 0.47, respectively (Figure S6).
For validating the SWATH-derived results, we developed a micro-HPLC PRM method which
included 27 proteotypic peptides from a total of nine proteins. Interestingly, these nine proteins
covered all the possible differences (up-regulated, down-regulated, or non-significant changes) for
both comparisons (DHA-MAG to control and ARA-MAG to control) as found in the SWATH analysis.
PRM [51], being a high-resolution (HR) MS targeted proteomics approach, has significantly greater
sensitivity, accuracy, and precision than non-targeted discovery measurements, and more specificity
than non-HR targeted methods, and therefore it is commonly used as a tool for validating protein
abundance changes in all kinds of quantitative proteomics applications [52]. The results from the PRM
assay were consistent with those previously found with the SWATH discovery approach (Table 1)
for both comparisons (DHA-MAG to control and ARA-MAG to control), in terms of significance,
fold-change, and direction of change (up- or down-regulation). Actually, the fold-changes were
very similar in both measures, SWATH and PRM. As some examples, MCM2 fold-changes for the
DHA-MAG to control comparison are 0.29 and 0.24, 0.40 and 0.38 for SRXn1, or 2.34 and 1.82 for
AIFM1, for SWATH and PRM, respectively. For the comparison of ARA-MAG to control, some
example fold-changes are 0.46 and 0.56 for MCM2, 4.81 and 5.12 for SRXN1, or 1.05 and 1.18 for
PSA3 (Table 1). Only protein PSMF1 showed a different behavior when comparing SWATH and PRM
analyses, and only for the ARA-MAG to control comparison (Table 1). While it had been found to be
down-regulated by SWATH, PRM analysis found a fold-change of 1.0 (and, accordingly, no statistically
significant difference). When inspecting the PRM results for this protein, we found that this issue could
be explained by a discordance between the measures for the two peptides that were monitored for this
protein: one of the peptides (ALIDPSSGLPNR) showed a fold-change of 0.56, while the fold-change for
the other peptide (LPPGAVPPGAR) was 1.41 (Table S7). On the other hand, this discordance between
the two peptides was not found in the comparison DHA-MAG to control, where the protein was found
to be significantly down-regulated in both PRM and SWATH measures.
An interesting finding of the PRM analysis was the validation of the strong down-regulation of
protein TEBP, prostaglandin E synthase 3, by DHA-MAG: measured fold-changes were 0.14 and 0.08
(SWATH and PRM, respectively), with adjusted p-values close to zero (Table 1), while ARA-MAG did
not affect this protein. Prostaglandin E synthase 3 is one of the main proteins in the prostaglandin
biosynthesis, converting prostaglandin H2 in prostaglandin E. Prostaglandin H2, the rate-limiting step
in the formation of prostaglandins, is the product of prostaglandin G/H synthase 2, or COX-2, which
has been related to colorectal cancer and whose inhibition (e.g., by nonsteroidal anti-inflammatory
drugs) has been linked to tumor cell apoptosis, inhibition of proliferation, and reduction of colorectal
cancer risk [53,54]. Therefore, it could be proposed that, apart from the proteasome pathway, one of the
mechanisms contributing to the anticancer activity of DHA-MAG in HT-29 cells is carried out through
the inhibition of prostaglandin synthesis, counteracting COX-2.
It should be noted here that an increase in lipid droplet accumulation, as a consequence of
a potential saturation of the cells by lipids, could have a role in some of the effects found. However,
we have demonstrated, and this is the main finding of this work, that, depending on the MAG,
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the molecular mechanisms working in the background are different, with DHA-MAG deeply affecting
the proteasome, with 30 proteins being strongly regulated, while ARA-MAG, with only two proteins
affected, does not. Actually, the conclusion of our study is that DHA- and ARA-MAG, while
differentially affecting the whole proteome of HT-29 cancer cells by means of different mechanisms are
not affected by the possibility of lipid droplets playing a role on the effect seen.
In summary, we have demonstrated that both ARA- and DHA-MAG showed concentration-
dependent inhibitory effects on HT-29 cell viability, with a clear ability of DHA-MAG to induce
cell death. The biological interpretation of SWATH-MS-generated proteomics data, validated by the
quantification of nine relevant proteins by PRM, revealed that DHA-MAG outperforms the effect
previously described for DHA-FFA, having a massive effect on the proteome of HT-29 cancer cells, with
the proteasome complex being completely shut down. The strong down-regulation of prostaglandin
E synthase 3, validated by PRM, also suggest a significant role of the prostaglandin synthesis in the
anticancer activity of DHA-MAG in these colorectal cancer cells. On the other hand, although the effect
of ARA-MAG is reduced in comparison to that of DHA-MAG, mainly in terms of inducing cell death,
it still produces concentration-dependent inhibitory effects on HT-29 cell viability, as revealed by the
MTT test. According to the proteomics experiments, this decrease of cell viability could be effected
through inhibition of DNA replication and G1/S cell cycle transition, as it was previously described for
ARA-FFA. Even though the MAG concentration used in the proteomics experiments (600 µM) could be
considered relatively high, previous studies have reported higher (above 1700 µM) FA concentrations
reached in human volunteers [55] and therefore, in the case of developing drugs based on MAG (and
the corresponding FFA) for the treatment of cancer, 600 µM would be physiologically achievable, and it
even would not represent negative effects on health, although, of course, further research in preclinical
models and also in the clinical setting should be needed.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/12/2984/s1,
Table S1: List of identified proteins in the integrated data set. FDR was set to 1% at both peptide and protein
levels. Table S2: SWATH-based protein quantification data for all the samples. 1882 proteins were quantified by
SWATH-MS and measures were normalized for inter-run variability as described in Material and Methods section.
Table S3: Differential abundance test for DHA-MAG vs. control. Fold changes, resulting p-values, and FDR analysis
q-values for each of the 1882 quantified proteins are shown. Table S4: Differential abundance test for ARA-MAG
vs. control. Fold changes, resulting p-values, and FDR analysis q-values for each of the 1882 quantified proteins
are shown. Table S5: GO analysis: biological processes. Differential expressed proteins found in each biological
process, together with all the proteins in that process, and the adjusted p-value, are shown for both comparisons,
DHA-MAG vs. control and ARA-MAG vs. control. Table S6: GO analysis: cellular components. Differential
expressed proteins found in each cellular component group, together with all the proteins in that component,
and the adjusted p-value, are shown for both comparisons, DHA-MAG vs. control and ARA-MAG vs control.
Table S7: Peptides selected for PRM validation. Fold-changes and adjusted p-values are shown for the comparisons
DHA-MAG to control and ARA-MAG to control, together with the coefficient of variation (CV) measured using
three technical replicates for each of the peptides. Figure S1: Multivariate analysis including all 1882 quantified
proteins, showing the complete separation of the samples from each group (DHA-MAG, ARA-MAG, and control).
(a) Group-averaged heat map; (b) partial least-squares discriminant analysis (PLS-DA); and (c) hierarchical cluster
analysis (Spearman distance). Figure S2: Coefficient of variation (CV) for the 27 peptides monitored in the PRM
validation, calculated using three injection replicates. Median CV for the PRM assay was 9%, with all peptides
but one showing a CV below 20%. Figure S3: Differentially expressed proteins found as effect of DHA- and
ARA-MAG, together with the previous results for DHA- and ARA-FFA [21]. Figure S4: Effect of ARA-MAG
extract on HT-29 cells (a) cell cycle pathway (KEGG: 04110), highlighting protein perturbation according to
our quantification results and showing coherent cascades; and (b) pyrimidine metabolism pathway (KEGG:
00240), highlighting significantly regulated proteins. Figure S5: Effect of DHA-MAG extract on HT-29 cells DNA
replication pathway (KEGG: 03030). (a) DNA replication pathway diagram highlighting significantly regulated
proteins. (b) Gene perturbation bar plot for DNA replication pathway affected proteins. Differentially expressed
genes are represented with negative values in blue and positive values in red. In this case all proteins highlighted
are under-regulated. Figure S6: Effect of ARA-MAG extract on HT-29 cells proteasome pathway (KEGG: 03050).
(a) Proteasome pathway diagram highlighting significantly regulated proteins. (b) Gene perturbation bar plot for
Proteasome pathway affected proteins. Differentially expressed proteins are represented with negative values in
blue and positive values in red. In this case all proteins highlighted are under-regulated. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with
the dataset identifier PXD014874.
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